Reviewer's report

Title: Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy.

Version: 0 Date: 28 Sep 2017

Reviewer: Ryszard Grenda

Reviewer's report:

This is a report on isolated, probably immune-mediated thrombocytopenia in renal transplant recipient. TMAT (transplant-mediated autoimmune thrombocytopenia) is rather related to liver transplantation and is more clinically dramatic.

From practical point the major issue is, that the diagnosis was not verified by detection of anti-platelets antibodies (anti-glycoprotein abs.). The test was not done, as the authors claim (basing on 2011 guidelines of American Society of Hematology) , that this is „not recommended as routine test” (page 6, row 43). It does not mean that the test should not be performed. Negative result in the presence of clinical overt isolated thrombocytopenia is doubtful, however positive result will clarify the mechanism of ITP in this case.

Thrombocytopenia in this case:
- was isolated
- was not related to any of diagnosed (and excluded) infections
- was not related to known drug toxicity
- responded to higher doses of steroids

therefore it is at least probable, that if anti-platelets abs. would be checked (prior to increasing steroids) - the result might be positive. This is important for further management of relapses (if will occur), because the patient, as diabetic one, sholud not be kept on higher steroids for long time. All treatment options mentioned in the discussion are related to ITP and it would be much easier to decide on further administration of expensive drug (such as rituximab) or IVIG or performing plasmapheresis (or splenectomy) - having baseline confirmation on antibodies against GPIIb/IIIa, GPIb and GPIaIIa platelet glycoproteins.
I suggest to discuss this in the discussion.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal